In April 2013, Vishva M. Dixit, M.D., Vice President of Physiological Chemistry at Genentech was elected to the Academy in recognition of his distinguished and continuing achievements in original research. Genentech co-founder Herb Boyer was elected to the Academy in 1985, Richard Scheller, Executive Vice President of Genentech Research & Early Development has been a member since 2000, and Ira Mellman, Vice President of Research Oncology at Genentech has been a member since 2011.

In January 2013, Genentech was included on FORTUNE's "100 Best Companies to Work For" list for the 15th consecutive year.

Genentech was also recognized on the "Top Companies" list for Most Women and Most Diverse, the "Big Pay" list for both Salaried Employees and Hourly Employees, and the "Best Benefits" list for Sabbaticals.

To pick the 100 Best Companies to Work For, FORTUNE partners with the Great Place to Work Institute (GPTWI) to conduct an employee survey of corporate America. Two-thirds of a company's score is based on the results of the institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third is based on responses to the institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, methods of internal communication, training, recognition programs, and diversity efforts.

In September 2012, Genentech was named one of the "top employer in the biopharmaceutical industry" by Science magazine. Science's annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries. This is the eleventh year Genentech has appeared on the list. We have been ranked the #1 company eight times.

In September 2012, Working Mother magazine named Genentech one of the "100 Best Companies for Working Mothers." The list ranks companies based on their workforce representation, childcare, flexibility programs, leave policies and more. For this year's list, particular weight was given to workforce profile, paid time off and company culture. This is the 19th year Genentech has appeared on the list.

In June 2012, FORTUNE magazine ranked Genentech number 63 on its list of "100 Top MBA Employers." The ranking is based on a survey by Universum research firm that asked 5,748 MBA students (2,109 women and 3,621 men) at 79 top business schools nationwide where they'd most like to work. This is the eighth time Genentech has appeared on the list.

In April 2012, the San Francisco Business Times named Genentech number ten on its list of the "Best Places to Work in the Bay Area." The ranking was decided largely on the basis of employee feedback via an online survey. Genentech was in the "giant companies" category, defined as having more than 1,501 employees. This is the ninth year that Genentech employees have participated in the survey, and the company has placed among the top five in the "giant companies" category each time.

In December 2011, Genentech was included on the Human Rights Campaign (HRC) Foundation's 2012 Corporate Equality Index (CEI) for the sixth consecutive year. Genentech has received a perfect score of 100 five times. Celebrating its 10th anniversary, the HRC Foundation Corporate Equality Index has served as a road map and progress report for major U.S. businesses' adoption of inclusive policies, practices and benefits for lesbian, gay, bisexual and transgender employees.

In June 2011, Computerworld ranked Genentech #4 in the large company category on its 18th annual "100 Best Places to Work in IT" list. Computerworld's annual ranking of the top work environments for technology professionals is based on a comprehensive questionnaire regarding company offerings in categories such as benefits, workplace diversity, career development, training opportunities, and employee retention. This year Genentech was also ranked as the 3rd best company for benefits and 2nd best company for diversity. This is the fourth year Genentech has appeared on the list.

On August 23, 2012, Genentech was selected as the "2012 Trailblazer Biotech Company of the Year" by PM360 Magazine. Genentech was selected based on our stellar achievements, and innovative policies and procedures within our company, community and the world arena. This year's award was based on three criteria: Innovation in Marketing and Advertising, Talent Development, and Social Responsibility.

On February 14, 2012, Genentech was named to Fast Company's 2012 "The World's 50 Most Innovative Companies" list for making targeted, genetics-based cancer therapies. According to the magazine, the list is comprised of companies "whose innovations are having an impact across their industries and our culture." Genentech was also ranked number two in the "Biotech Industry" category.

On November 11, 2010, Genentech received the 3rd Annual American Institute of Chemical Engineers' (AIChE) Corporate Innovation Award, which recognizes corporations employing a substantial number of chemical engineers for innovation in research and development, for development of new technologies, for technology transfer and/or for bringing new products to the marketplace. Criteria for selection was based on impact in the marketplace and global community, magnitude of the challenges that were overcome and intellectual content of the innovation and technical creativity. Genentech joined previous award winners Dupont (2009) and 3M (2008).

In July 2012, the San Francisco Business Times ranked Genentech number nine on its list of "Top Bay Area Corporate Philanthropists" at the annual Bay Area Corporate Philanthropy Summit and Awards. This is the seventh consecutive year the company has appeared on the list.

On September 21, 2012, Ian Clark was selected as the San Francisco Business Times 2012 Most Admired CEO in the Public Companies category. The Bay Area's Most Admired CEO Awards recognizes outstanding Bay Area CEOs.

On July 23, 2012, Art Levinson was selected to receive the Cold Spring Harbor Laboratory (CSHL) Double Helix Medal. The Double Helix Medal recognizes esteemed individuals who have positively impacted human health by raising awareness and funds for biomedical research. Recipients of the Double Helix Medal have boldly participated in the fight to find cures for the diseases that plague us. Art Levinson pioneered a new generation of novel therapeutic strategies through his leadership of Genentech, delivering groundbreaking therapies such as Herceptin, Avastin and Rituxan to patients around the world.

On April 26, 2012, Jennifer Cook, Senior Vice President of U.S. Sales and Marketing for Immunology and Ophthalmology, was named by San Francisco Business Times as one of the Bay Area's 2012 "Most Influential Women in Business." The San Francisco Business Times honors top women executives at Bay Area corporations and large public, nonprofit and government organizations. The annual list recognizes 150 outstanding women professionals who make a difference in their companies, industries and communities.

Sara Kenkare-Mitra, Ph.D., Vice President and Head of Development Science of Genentech Research & Early Development and Ann L. Lee, Ph.D., Senior Vice President of Genentech and Head of Global Technical Development for Roche were both named one of "Most Influential Women in Business" in 2011, and Sandra J. Horning, Ph.D, Senior Vice President and Global Head of Hematology/Oncology Clinical Development was named one of the "Most Influential Women in Business" in 2010.

On March 25, 2011, Art Levinson, Ph.D., chairman and former CEO of Genentech Inc., received the Fifth Annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 102nd Annual Meeting in Orlando, FL. This award recognizes an individual whose leadership and extraordinary achievements in cancer research, or in support of cancer research, have made a major impact on the field.

On February 11, 2011, Ian Clark, Chief Executive Officer, Genentech and Head of North American Commercial Operations for Roche was named by the Healthcare Businesswomen's Association (HBA) as its 2011 Honorable Mentor. Ian was recognized for "his dedication to enhancing and accelerating the stature and accomplishments of women in healthcare." The HBA created the Honorable Mentor award eleven years ago to recognize one individual each year who demonstrates long-term support of the advancement of women in the healthcare industry, has a personal dedication to developing, mentoring and promoting women in the industry, and who has been supportive of the HBA.

On June 3, 2010, Genentech's Richard Scheller, Ph.D., Executive Vice President of Genentech Research and Early Development (gRED), was named a winner of the 2010 Kavli Prize in Neuroscience, awarded for outstanding achievement in advancing knowledge and understanding of the brain and nervous system. The Kavli Prizes, presented every two years in Oslo, Norway in cooperation with the Norwegian Academy of Sciences and Letters, recognize scientists for their seminal advances in the research areas of astrophysics, nanoscience and neuroscience.

On May 5, 2010, Art Levinson received the Biotechnology Heritage Award for his "contributions to the growth of biotechnology through discovery, innovation and commercialization." The award was given at a luncheon at the Biotechnology Industry Organization's (BIO) annual meeting in Chicago, Ill. In the 12 years that BIO and the Chemical Heritage Foundation have given the award, now three recipients have come from Genentech. Genentech founders Herbert Boyer and the late Robert Swanson received the award in 2000.

On November 25, 2009, Olive Tree Publishing, Inc., publishers of the Black EOE Journal, Hispanic Network Magazine and Professional Woman's Magazine, announced that Genentech has been selected and will be recognized in the publication's 2009 "Best of the Best" Annual Review Series. The annual evaluation, now in its 18th year, sets the standard for identifying corporations that are providing the best career opportunities for minorities.

On November 25, 2009, Olive Tree Publishing, Inc., publishers of the Black EOE Journal, Hispanic Network Magazine and Professional Woman's Magazine, announced that Genentech has been selected and will be recognized in the publication's 2009 "Best of the Best" Annual Review Series. The annual evaluation, now in its 18th year, sets the standard for identifying corporations that are providing the best career opportunities for minorities.

On March 4, 2010, FORTUNE magazine named Roche number four in the Pharmaceuticals category on its 2010 list of "America's Most Admired" companies. To compile the list, FORTUNE asked executives, directors and securities analysts to rate the largest companies within their industries based on innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment, quality of products/services and global competitiveness. Genentech ranked number one in the Pharmaceutical category for two consecutive years before contributing to the ranking as a wholly owned member of the Roche Group in 2010.

Diversity Employers Magazine's (formerly Black Collegian Magazine) Top 100 Employers is now available online. Genentech is included in the Additional Top Employers Actively Recruiting for the Class of 2011, a supplementary list to the Top 50 ranking. Diversity Employers only ranked 19 companies as Additional Top Employers in 2011 compared to 58 companies in 2010. Genentech was previously not included in 2010.

None of Genentech's competitors are ranked in 2011. In 2010, AstraZeneca ranked #92, recruiting 60 students at 15 campuses.

The "Top 100 Employers of the Class of 2011 and the Majors in Demand" will be published in the Winter 2011 Premier Issue of Diversity Employers and online at DiversityEmployers.com.